Study patient characteristic
| . | All patients (n = 723) . | Other B-ALL (n = 706) . | CDX2/UBTF ALL (n = 17) . | P value . |
|---|---|---|---|---|
| Patient-related characteristics | ||||
| Median age, y (range) | 38 (18-60) | 38 (18-60) | 31 (19-50) | .13 |
| Gender, M/F (ratio) | 400/323 (1.2) | 397/309 (1.3) | 3/14 (0.2) | .002 |
| Disease-related characteristics | ||||
| Median WBC, G/L (range) | 9 (0-712) | 9 (0-712) | 9 (1-63) | .72 |
| BM blast percentage (range) | 91 (21-100) | 91 (21-100) | 81 (35-98) | .04 |
| CNS involvement | 57/713 (8%) | 57/696 (8%) | 0/17 (0%) | .39 |
| Immunophenotypic classification (EGIL) | <.001 | |||
| Pro-B (I) | 148/622 (24%) | 136/605 (22%) | 12/17 (71%) | |
| Common (II) | 364/622 (59%) | 361/605 (60%) | 3/17 (18%) | |
| Pre-B (III) | 102/622 (16%) | 100/605 (17%) | 2/17 (12%) | |
| Mature (IV) | 8/622 (1%) | 8/605 (1%) | 0/17 (0%) | |
| Response-related characteristics | ||||
| Good PB prednisone response at day 8 | 582/701 (83%) | 574/685 (84%) | 8/16 (50%) | .002 |
| Good BM response at day 15 | 397/668 (59%) | 395/653 (60%) | 2/15 (13%) | <.001 |
| Late CR (achieved after induction 2) | 24/672 (4%) | 21/656 (3%) | 3/16 (19%) | .017 |
| CR (after induction 1 and 2) | 672/723 (93%) | 656/706 (93%) | 16/17 (94%) | 1.0 |
| Postinduction MRD ≥10-4 | 255/542 (47%) | 242/528 (46%) | 13/14 (93%) | <.001 |
| Postinduction MRD ≥10-3 | 151/542 (28%) | 144/528 (27%) | 7/14 (50%) | .073 |
| Postremission outcome | ||||
| Allo-SCT in first CR | 184/672 (27%) | 174/656 (27%) | 10/16 (63%) | .003 |
| 3-y CIR, % (95% CI) | 33.5 (29.8-37.6) | 32.4 (28.7-36.5) | 75.0 (50.6-93.5) | .004 |
| 3-y OS, % (95% CI) | 65.9 (62.0-69.5) | 65.9 (61.9-69.5) | 67.9 (38.8-85.4) | .86 |
| . | All patients (n = 723) . | Other B-ALL (n = 706) . | CDX2/UBTF ALL (n = 17) . | P value . |
|---|---|---|---|---|
| Patient-related characteristics | ||||
| Median age, y (range) | 38 (18-60) | 38 (18-60) | 31 (19-50) | .13 |
| Gender, M/F (ratio) | 400/323 (1.2) | 397/309 (1.3) | 3/14 (0.2) | .002 |
| Disease-related characteristics | ||||
| Median WBC, G/L (range) | 9 (0-712) | 9 (0-712) | 9 (1-63) | .72 |
| BM blast percentage (range) | 91 (21-100) | 91 (21-100) | 81 (35-98) | .04 |
| CNS involvement | 57/713 (8%) | 57/696 (8%) | 0/17 (0%) | .39 |
| Immunophenotypic classification (EGIL) | <.001 | |||
| Pro-B (I) | 148/622 (24%) | 136/605 (22%) | 12/17 (71%) | |
| Common (II) | 364/622 (59%) | 361/605 (60%) | 3/17 (18%) | |
| Pre-B (III) | 102/622 (16%) | 100/605 (17%) | 2/17 (12%) | |
| Mature (IV) | 8/622 (1%) | 8/605 (1%) | 0/17 (0%) | |
| Response-related characteristics | ||||
| Good PB prednisone response at day 8 | 582/701 (83%) | 574/685 (84%) | 8/16 (50%) | .002 |
| Good BM response at day 15 | 397/668 (59%) | 395/653 (60%) | 2/15 (13%) | <.001 |
| Late CR (achieved after induction 2) | 24/672 (4%) | 21/656 (3%) | 3/16 (19%) | .017 |
| CR (after induction 1 and 2) | 672/723 (93%) | 656/706 (93%) | 16/17 (94%) | 1.0 |
| Postinduction MRD ≥10-4 | 255/542 (47%) | 242/528 (46%) | 13/14 (93%) | <.001 |
| Postinduction MRD ≥10-3 | 151/542 (28%) | 144/528 (27%) | 7/14 (50%) | .073 |
| Postremission outcome | ||||
| Allo-SCT in first CR | 184/672 (27%) | 174/656 (27%) | 10/16 (63%) | .003 |
| 3-y CIR, % (95% CI) | 33.5 (29.8-37.6) | 32.4 (28.7-36.5) | 75.0 (50.6-93.5) | .004 |
| 3-y OS, % (95% CI) | 65.9 (62.0-69.5) | 65.9 (61.9-69.5) | 67.9 (38.8-85.4) | .86 |
For BM blast percentage, data were available for 423 patients. Good PB prednisone response at day 8 is defined by less than 1 G/L blast. Good BM response at day 15 is defined by <5% blast. MRD evaluation was performed by PCR quantification of immunoglobulin or T-cell receptor clono-specific rearrangements according to EuroMRD guidelines.
Allo-SCT, allogeneic stem cell transplantation; BM, bone marrow; CNS, central nervous system; CR, complete remission; EGIL, European Group for the Immunological Characterization of Leukemias; F, female; M, male; MRD, minimal residual disease; OS, overall survival; PB, peripheral blood.